News about 'markets'

29 Apr 2014
The European Commission has approved Delaminid (Deltyba™) for use in patients suffering from MDR-TB. Delamanid was developed by Otsuka Pharmaceutical Co., Ltd., a Japanese pharmaceutical company dedicated to drug discovery for tuberculosis. The press release from Otsuka can be found here Related...
6 Mar 2014
The European Medicines Agency (EMA) has recently approved Sirturo (bedaquiline) for conditional use in the European Union for adults suffering from pulmonary MDR-TB. The press release from Multimedia News Release can be found at: http://www.multivu.com/mnr/65014-sirturo-treatment-multi-drug-...
25 Nov 2013
Source: European Medicines Agency http://www.ema.europa.eu On 21 November 2013, the Committee for Medicinal Products for Human Use (CHMP) recommended the granting of a conditional marketing authorisation for the medicinal product Deltyba for the treatment of lung infections due to multidrug-...
29 Jul 2013
Source: Bloomberg http://www.bloomberg.com/news/2013-07-26/otsuka-s-drug-resistant-tb-treatment-fails-to-win-ema-nod.html Otsuka’s Drug-Resistant TB Treatment Fails to Win EMA Nod Otsuka Holdings Co. (4578) failed to win the backing of a European Medicines Agency panel for the Delamanid medicine...
30 Jun 2013
Click here to access full report Source: Treatment Action Group The Tuberculosis Treatment Pipeline June 2013 Better than Ever Is Not Good Enough By Erica Lessem Introduction In December 2012, tuberculosis (TB) treatment reached a historic landmark with the first approval by a stringent regulatory...
25 Apr 2013
Treatment Action Group (TAG) recently released its Spring 2013 issue of tagline, which contains three articles about TB research that might be of interest to you– 1) on rifapentine research and access , 2) on adaptive clinical trial designs , and 3) on pediatric drug development needs . The full...
5 Jan 2013
Press Release from FDA can be found at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333695.htm . Press Release from Janssen is below. FDA Grants Accelerated Approval for SIRTURO™ (bedaquiline) as Part of Combination Therapy to Treat Adults with Pulmonary Multi-Drug Resistant...
3 May 2011
The first detailed study of the private tuberculosis (TB) drug market, published on May 4 th , in the PLoS ONE journal, finds that the market is surprisingly large, and has irregular practices that could be driving treatment failures and contributing to the emergence of multidrug-resistant TB (MDR-...
7 Dec 2010
WHO Press Conference Yesterday, Mario Raviglione , Director of Stop TB, and Giorgio Roscigno, CEO of FIND, held a global press conference announcing the World Health Organization’s endorsement of the new rapid diagnostic test Xpert MTB/RIF. If implemented to scale in countries where tuberculosis (...
8 Aug 2010
Originally posted on DailyFinance: http://srph.it/d7qPd8 . AOL Daily Finance GlaxoSmithKline ( GSK ) researchers announced Wednesday that they have found a new compound that may help in the fight against drug-resistant bacteria. The findings could ultimately assist scientists in developing new...
19 Apr 2010
Despite the massive need for new TB drugs, the commercial viability of the TB drug market has long been viewed as questionable at best. Reports suggest that there is a substantial market that will grow year-over-year, though there is no firm conclusion about its commercial viability. The first...